SpaRx: Elucidate Single-cell Spatial Heterogeneity of Drug Responses for Personalized Treatment

Overview

Journal Brief Bioinform

Publisher Oxford University Press

Specialty Biology

Date 2023 Oct 5

PMID 37798249

Authors

Ziyang Tang

Xiang Liu

Zuotian Li

Tonglin Zhang

Baijian Yang

Jing Su

Qianqian Song

Affiliations

Soon will be listed here.

Abstract

Spatial cellular authors heterogeneity contributes to differential drug responses in a tumor lesion and potential therapeutic resistance. Recent emerging spatial technologies such as CosMx, MERSCOPE and Xenium delineate the spatial gene expression patterns at the single cell resolution. This provides unprecedented opportunities to identify spatially localized cellular resistance and to optimize the treatment for individual patients. In this work, we present a graph-based domain adaptation model, SpaRx, to reveal the heterogeneity of spatial cellular response to drugs. SpaRx transfers the knowledge from pharmacogenomics profiles to single-cell spatial transcriptomics data, through hybrid learning with dynamic adversarial adaption. Comprehensive benchmarking demonstrates the superior and robust performance of SpaRx at different dropout rates, noise levels and transcriptomics coverage. Further application of SpaRx to the state-of-the-art single-cell spatial transcriptomics data reveals that tumor cells in different locations of a tumor lesion present heterogenous sensitivity or resistance to drugs. Moreover, resistant tumor cells interact with themselves or the surrounding constituents to form an ecosystem for drug resistance. Collectively, SpaRx characterizes the spatial therapeutic variability, unveils the molecular mechanisms underpinning drug resistance and identifies personalized drug targets and effective drug combinations.

Citing Articles

The Impact of Klotho in Cancer: From Development and Progression to Therapeutic Potential.

Ortega M, Boaru D, De Leon-Oliva D, De Castro-Martinez P, Minaya-Bravo A, Casanova-Martin C Genes (Basel). 2025; 16(2).

PMID: 40004457 PMC: 11854833. DOI: 10.3390/genes16020128.

High-throughput gene expression analysis with TempO-LINC sensitively resolves complex brain, lung and kidney heterogeneity at single-cell resolution.

Eastburn D, White K, Jayne N, Camiolo S, Montis G, Ha S Sci Rep. 2024; 14(1):31285.

PMID: 39732835 PMC: 11682069. DOI: 10.1038/s41598-024-82736-6.

Single cell spatial profiling of FFPE splenic tissue from a humanized mouse model of HIV infection.

Wu G, Keller S, Sardo L, Magliaro B, Zuck P, Balibar C Biomark Res. 2024; 12(1):116.

PMID: 39380117 PMC: 11462831. DOI: 10.1186/s40364-024-00658-x.

AntiFormer: graph enhanced large language model for binding affinity prediction.

Wang Q, Feng Y, Wang Y, Li B, Wen J, Zhou X Brief Bioinform. 2024; 25(5).

PMID: 39162312 PMC: 11333967. DOI: 10.1093/bib/bbae403.

Advances in spatial transcriptomics and its applications in cancer research.

Jin Y, Zuo Y, Li G, Liu W, Pan Y, Fan T Mol Cancer. 2024; 23(1):129.

PMID: 38902727 PMC: 11188176. DOI: 10.1186/s12943-024-02040-9.

References

He S, Bhatt R, Brown C, Brown E, Buhr D, Chantranuvatana K . High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. Nat Biotechnol. 2022; 40(12):1794-1806. DOI: 10.1038/s41587-022-01483-z. View

Yosef G, Hayun H, Papo N . Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy. Biochem J. 2021; 478(5):1139-1157. PMC: 7959692. DOI: 10.1042/BCJ20200628. View

Katayama H, Ueoka H, Kiura K, Tabata M, Kozuki T, Tanimoto M . Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer. 2004; 90(5):979-84. PMC: 2409628. DOI: 10.1038/sj.bjc.6601624. View

Li X, Hu Z, Shi H, Wang C, Lei J, Cheng Y . Inhibition of VEGFA Increases the Sensitivity of Ovarian Cancer Cells to Chemotherapy by Suppressing VEGFA-Mediated Autophagy. Onco Targets Ther. 2020; 13:8161-8171. PMC: 7443464. DOI: 10.2147/OTT.S250392. View

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

Sofeu Feugaing D, Gotte M, Viola M . More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol. 2012; 92(1):1-11. DOI: 10.1016/j.ejcb.2012.08.004. View

Nirmal A, Maliga Z, Vallius T, Quattrochi B, Chen A, Jacobson C . The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Cancer Discov. 2022; 12(6):1518-1541. PMC: 9167783. DOI: 10.1158/2159-8290.CD-21-1357. View

Gubbiotti M, Vallet S, Ricard-Blum S, Iozzo R . Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions. Matrix Biol. 2016; 55:7-21. PMC: 6938589. DOI: 10.1016/j.matbio.2016.09.009. View

El-Sayes N, Vito A, Mossman K . Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy. Cancers (Basel). 2021; 13(4). PMC: 7918981. DOI: 10.3390/cancers13040806. View

10.

Luca B, Steen C, Matusiak M, Azizi A, Varma S, Zhu C . Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell. 2021; 184(21):5482-5496.e28. PMC: 8526411. DOI: 10.1016/j.cell.2021.09.014. View

11.

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M . Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020; 18(1):59. PMC: 7140346. DOI: 10.1186/s12964-020-0530-4. View

12.

Maacha S, Bhat A, Jimenez L, Raza A, Haris M, Uddin S . Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Mol Cancer. 2019; 18(1):55. PMC: 6441157. DOI: 10.1186/s12943-019-0965-7. View

13.

Albini A, Noonan D . Decidual-Like NK Cell Polarization: From Cancer Killing to Cancer Nurturing. Cancer Discov. 2020; 11(1):28-33. DOI: 10.1158/2159-8290.CD-20-0796. View

14.

Kaya A, Buyukberber S, Benekli M, Coskun U, Sevinc A, Akmansu M . Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer. Med Oncol. 2009; 27(1):152-7. DOI: 10.1007/s12032-009-9186-z. View

15.

Lewis S, Asselin-Labat M, Nguyen Q, Berthelet J, Tan X, Wimmer V . Spatial omics and multiplexed imaging to explore cancer biology. Nat Methods. 2021; 18(9):997-1012. DOI: 10.1038/s41592-021-01203-6. View

16.

Grugan K, Miller C, Yao Y, Michaylira C, Ohashi S, Klein-Szanto A . Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci U S A. 2010; 107(24):11026-31. PMC: 2890722. DOI: 10.1073/pnas.0914295107. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Yang G, Fan J, Xu Y, Qiu S, Yang X, Shi G . Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist. 2008; 13(11):1155-65. DOI: 10.1634/theoncologist.2008-0081. View

19.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

20.

Ding Z, Zu S, Gu J . Evaluating the molecule-based prediction of clinical drug responses in cancer. Bioinformatics. 2016; 32(19):2891-5. DOI: 10.1093/bioinformatics/btw344. View